Research Progress on the Therapeutic Effects of
Yinchenhao Decoction in the Treatment of Metabolic Associated Fatty Liver
Disease

doi:10.1009-0959.2025.120013

Abstract

Abstract:

In recent years， the prevalence of metabolic dysfunction-associated fatty liver disease （MAFLD） has been steadily increasing， while safe and effective therapeutic agents remain lacking. Against this background， the potential of Yinchenhao Decoction （YCHD） in the intervention of MAFLD has attracted growing attention. This review systematically summarizes recent advances in basic and clinical studies on the therapeutic effects and mechanisms of YCHD in MAFLD. Current evidence indicates that YCHD exerts multi-target and multi-pathway regulatory effects by modulating lipid metabolism， maintaining bile acid homeostasis， alleviating oxidative stress， and improving gut-liver axis dysfunction， thereby significantly improving liver function and lipid profiles and reducing hepatocellular injury. YCHD demonstrates unique advantages in the prevention and treatment of MAFLD； however， most mechanistic studies focus on single pathways. Future research should emphasize more in-depth experimental studies and high-quality clinical trials to comprehensively elucidate its pharmacological mechanisms， providing a solid theoretical basis and new perspectives for the role of traditional Chinese medicine in MAFLD management.

Key words: Yinchenhao Decoction； , Metabolic dysfunction-associated fatty liver disease； , Mechanisms of action； , Research progress

CLC Number:

CHEN Guoyang, HAN Xiuzhen, SHANG Jingyu, SHANG Hongtao.

Research Progress on the Therapeutic Effects of Yinchenhao Decoction in the Treatment of Metabolic Associated Fatty Liver Disease [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2026, 28(2): 146-146-150.

References

［1］ Cai Y，Fang L，Chen F，et al. Targeting AMPK related signaling pathways： A feasible approach for natural herbal medicines to intervene non-alcoholic fatty liver disease［J］.J Pharm Anal， 2025，15（1）：101052.

［2］ Shi R，Chai K，Wang H，et al. Clinical assessment of common medications for nonalcoholic fatty liver disease： a systematic review and Bayesian network meta-analysis［J］.J Evid Based Med， 2025，18（1）：e70002.

［3］ Mansour RM，Abdel Mageed SS，Abulsoud AI，et al. From fatty liver to fibrosis： the impact of miRNAs on NAFLD and NASH［J］.Funct Integr Genomics， 2025，25（1）：30.

［4］ Wan X，Ma J，Bai H，et al. Drug advances in NAFLD： Individual and combination treatment strategies of natural products and small-synthetic-molecule drugs［J］.Biomolecules， 2025，15（1）：88.

［5］姚一青，曹奇，王璇，等.基于UPLC-QTOF/MS的茵陈蒿汤体外成分鉴定和急性肝损伤防护作用入血成分研究［J］.药学学报，2023，58（5）：1173-1180.

［6］刘军舰，袁红霞，张井虹，等.茵陈蒿汤治疗热重于湿证阻塞性黄疸患者的临床疗效研究［J］.中国中西医结合外科杂志，2024，30（1）：90-94.

［7］左璐，崔付超.加味茵陈蒿汤治疗湿热内蕴型肝硬化临床研究［J］.河南中医，2023，43（3）：350-353.

［8］王艳，宋丽.加味茵陈蒿汤联合针刺对非酒精性脂肪肝患者肠道菌群、氧化应激及细胞因子的影响［J］.现代中西医结合杂志，2023，32（8）：1119-1122.

［9］陈文增，姚颖玉，王庆敏，等.加味茵陈蒿汤联合熊去氧胆酸治疗湿热蕴结型妊娠期肝内胆汁淤积症28例［J］.浙江中医杂志，2025，60（2）：133-135.

［10］洪礼虎.加味茵陈蒿汤对慢性持续期支气管哮喘疗效及炎症因子的影响［J］.中医临床研究，2022，14（14）：126-128.

［11］滕飞，骆欢.加味茵陈蒿汤治疗湿热中阻型乙型病毒性肝炎患者的效果［J］.中外医学研究，2025，23（4）：1-5.

［12］郑玉娇，苟筱雯，丁齐又，等.态靶辨证在非酒精性脂肪肝中的运用——茵陈蒿汤加虎杖、鬼箭羽［J］.辽宁中医杂志，2020，47（8）：4-6.

［13］周强，陶琳，张声生.代谢相关脂肪性肝病的中医认识及辨治［J］.中华中医药杂志，2021，36（11）：6380-6384.

［14］赵嘉晶，汪颖珏，朱永新，等.茵陈蒿汤加减方对非酒精性脂肪肝患者糖、脂及尿酸代谢的影响［J］.四川中医，2018，36（3）：112-114.

［15］刘悦.茵陈蒿汤加减对非酒精性脂肪肝湿热证患者肠道微生态的影响［J］.辽宁中医杂志，2021，48（3）：115-118.

［16］罗华兵，何文忠，李东生，等.加味茵陈蒿汤治疗非酒精性脂肪肝的临床疗效及对肠道菌群影响［J］.世界中西医结合杂志， 2021，16（9）：1746-1750.

［17］冯健茹，许光远.茵陈蒿汤合四逆散治疗非酒精性脂肪肝伴高同型半胱氨酸血症临床观察［J］.中国实验方剂学杂志， 2019，25（16）：61-66.

［18］孙晓红，张良登，苏晓兰，等.非酒精性脂肪肝的中医多维度辨治［J］.世界中西医结合杂志，2014，9（8）：888-892.

［19］张鼎. 茵陈蒿汤加减方联合二甲双胍治疗非酒精性脂肪肝对血糖血脂及尿酸代谢的影响［J］.实用中医药杂志，2019，35（8）：956-957.

［20］陈振道，王亚瑞，祝斌，等.茵陈蒿汤联合酪酸梭菌治疗老年非酒精性脂肪肝病的疗效观察［J］.中医临床研究，2020，12（7）：47-49.

［21］顾文. 茵陈蒿汤联合肠道益生菌治疗非酒精性脂肪性肝病的疗效探讨［J］.中国中西医结合消化杂志，2021，29（10）：745-748.

［22］宋丽，石蕊，赵香君.手足十二针联合加味茵陈蒿汤治疗非酒精性脂肪肝及对患者肠道菌群的影响［J］.陕西中医，2022，43（2）：252-256.

［23］ Lefebvre P，Cariou B，Lien F，et al. Role of bile acids and bile acid receptors in metabolic regulation［J］.Physiol Rev， 2009，89（1）：147-191.

［24］ Eloranta JJ，Kullak-Ublick GA. The role of FXR in disorders of bile acid homeostasis［J］.Physiology （Bethesda）， 2008，23：286-295.

［25］ Kunst RF，Verkade HJ，Oude Elferink RPJ，et al. Targeting the four pillars of enterohepatic bile salt cycling： Lessons from genetics and pharmacology［J］.Hepatology， 2021，73（6）：2577-2585.

［26］刘馨烛.基于FXR探讨茵陈蒿汤调控非酒精性脂肪性肝病合并胆汁淤积小鼠胆汁酸和脂肪代谢效应机制研究［D］.上海：上海中医药大学，2019.

［27］付亚坤，闫丽辉，李新，等.茵陈蒿汤防治大鼠非酒精性脂肪性肝病效果及其对肝组织NTCP表达的影响［J］.山东医药，2019，59（2）：40-43.

［28］杜曾.茵陈蒿汤组分调控代谢相关脂肪性肝病合并胆汁淤积小鼠胆汁酸和脂肪代谢的机制研究［D］.上海：上海中医药大学，2021.

［29］邱剑楠.基于肠道菌群多样性、代谢组学探讨茵陈蒿汤及其组分调控代谢相关脂肪性肝病效应机制研究［D］.上海：上海中医药大学，2020.

［30］刘宝莹，黄艳阳，杨思琦，等.茵陈蒿汤对代谢相关脂肪性肝病小鼠XOD介导NLRP3炎症小体信号通路的影响［J］.时珍国医国药，2025，36（1）：34-39.

［31］ Kumar S，Duan Q，Wu R，et al. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis［J］.Adv Drug Deliv Rev， 2021，176：113869.

［32］郭一，李军祥，毛堂友，等.苓桂术甘汤与茵陈蒿汤合方对非酒精性脂肪性肝炎大鼠Nrf2/ARE信号通路的影响［J］.中国实验方剂学杂志， 2017，23（16）：108-113.

［33］乔治园，郭峰，陈彦竹，等.芪茵颗粒对非酒精性脂肪性肝病大鼠胰岛素抵抗和CYP2E1表达的影响［J］.现代中西医结合杂志，2017，26（3）：229-233.

［34］谭婷，何栋，朱红梅，等.茵陈蒿汤对非酒精性脂肪性肝病大鼠细胞色素氧化酶P450-2E1影响研究［J］.吉林中医药， 2020，40（11）：1505-1508.

［35］ Wiering L，Tacke F. Treating inflammation to combat non-alcoholic fatty liver disease［J］.J Endocrinol， 2023，256（1）：15-30.

［36］ Han J，Wu J，Silke J. An overview of mammalian p38 mitogen-activated protein kinases， central regulators of cell stress and receptor signaling［J］.F1000Res， 2020，9：1028.

［37］ Zhao W，Yan Y，Xiao Z，et al. Bicyclol ameliorates nonalcoholic fatty liver disease in mice via inhibiting MAPKs and NF-kappaB signaling pathways［J］.Biomed Pharmacother， 2021，141：111874.

［38］ Zhu X，Zeng C，Yu B. White adipose tissue in metabolic associated fatty liver disease［J］.Clin Res Hepatol Gastroenterol， 2024，48（5）：102336.

［39］周伟青，刘道利，王修银，等.茵陈蒿汤对非酒精性脂肪肝伴糖尿病大鼠p38丝裂原活化蛋白激酶表达的影响［J］.实用医学杂志，2019，35（18）：2840-2843.

［40］王海伦.茵陈蒿汤治疗非酒精性脂肪肝病机理研究［D］.南京：南京中医药大学，2019.

［41］ Rattanaprasert M，van Pijkeren J，Ramer-Tait AE，et al. Genes involved in galactooligosaccharide metabolism in lactobacillus reuteri and their ecological role in the gastrointestinal tract［J］.Appl Environ Microbiol， 2019，85（22）：e01448-19.

［42］ Nicoletti A，Ponziani FR，Biolato M，et al. Intestinal permeability in the pathogenesis of liver damage： from non-alcoholic fatty liver disease to liver transplantation［J］.World J Gastroenterol， 2019，25（33）：4814-4834.

［43］ Jiang X，Zheng J，Zhang S，et al. Advances in the involvement of gut microbiota in pathophysiology of NAFLD［J］.Front Med （Lausanne）， 2020，7：361.

［44］李自辉，张娜，王宇，等.基于16S rRNA技术与代谢组学探究茵陈蒿汤治疗非酒精性脂肪肝的作用机制［J］.中华中医药杂志，2019，34（5）：1908-1913.

[1]	YAN Jingli, WU Hong. Research Progress of the Classic Prescription Danggui Shaoyao Powder for Treatment of Chest Impediment [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2026, 28(2): 165-165-168.
[2]	AN Fan, ZHAI Yuze, WANG Xiaoyu, WANG Benjun. Research Progress on the Treatment of Crohn's Disease with Vedolizumab [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(7): 674-680.
[3]	LI Jianhong, LV Ruiping, TIE Minghui, REN Kangzon, GONG Ruiying. Research Progress on Active Ingredients of Traditional Chinese Medicine Regulating Cell Pyroptosis and Preventing Sepsis [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(5): 458-463.
[4]	LU Chang, CHEN Guanzheng, XU Liran, YUE Jingyu. Research Progress on Modern Clinical Application and Mechanism of Action of Banxia Houpu Decoction [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(5): 452-457.
[5]	LI Shuai, HU Xiaoyang, ZUO Jun. Research Progress on Pharmacological Effects of Pueraria lobata Extract in the Prevention and Treatment of Diabetes Mellitus [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(4): 343-348.
[6]	LU Cuncun, WANG Haibo, ZHANG Qiang, WANG Zhifei. Knowledge Mapping of Traditional Chinese Medicine for Metabolic Dysfunction-associated Steatotic Liver Disease based on CNKI [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(11): 1215-1215-1223.
[7]	YANG Shu, PU Jian, ZHANG Jiazhen, DING Jinju, LIU Bin. Research Progress of In-vitro Test on Biotribocorrosion in the Field of Orthopaedic Trauma Surgery [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(1): 27-33.
[8]	ZHAO Yajie, LIANG Hansheng. Research Progress on the Mechanism of Thermoregulation [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2025, 27(1): 34-40.
[9]	ZHANG Xiangyue. Research Progress in the Treatment of Acute Conjunctivitis with Traditional Chinese Medicine [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2024, 26(9): 892-895.
[10]	FAN Lingling, YIN Li, WANG Shigong, ZHANG Ying, GESANG Dunzhu, LI Chunyan, LI Jingxin. Research Progress on Health Risks and Potential Wellness Effects in Plateau Areas [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2024, 26(8): 755-763.
[11]	JIANG Lan, LU Yongchao. Research Progress on Non-Coding RNA Related to Endometriosis [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2024, 26(5): 450-454.
[12]	SUN Huiting, ZHUANG Lingling. Research Progress on Treatment of Children Adenoidal Hypertrophy with Traditional Chinese and Western Medicine and Its Effect on Levels of Interleukins [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2024, 26(5): 484-488.
[13]	YAN Bisong. Research Progress on the Clinical Three-Dimensional Mechanism of Active Ingredients of Gouteng [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2024, 26(4): 374-377.
[14]	HU Yixuan, ZHOU Zikai, . Research and Application of Antisense Oligonucleotide in the Treatment of Nervous System Diseases [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2024, 26(4): 345-352.
[15]	ZHANG Pei, LI Fei. Research Progress on Extraction and Purification Process of Active Ingredients from Phyllanthus Urinaria Land Quality Control [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2024, 26(4): 378-383.

Research Progress on the Therapeutic Effects of Yinchenhao Decoction in the Treatment of Metabolic Associated Fatty Liver Disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments